Source Articles
Pembrolizumab
Showing 9 study arms
with grade ≥3 adverse event data (treatment-related and RT-related).
Click a column header to sort.
Note on patient counts: some articles reported only percentages rather
than absolute numbers. Where this occurred, the number of patients — including those with
grade ≥3 adverse events — was derived by applying the reported percentage to the total arm
size, which may produce a non-integer value. These figures have been rounded to the nearest
integer for display.
| 1st Author | Year | Study Type | Title | DOI | clinical trial number | number of patients | median/mean age | median follow-up [months] | tumor type | treatment setting | drug group | drug name | if other, please specify | number of SBRT courses | intracranial / extracranial | treated site | If other treated site, please specify | median/mean total RT dose [Gy] | minimum total RT dose [Gy] | maximum total RT dose [Gy] | median/mean number of fractions | minimum number of fractions | maximum number of fractions | median/mean dose per fraction [Gy] | minimum dose per fraction [Gy] | maximum dose per fraction [Gy] | toxicity type | patients with acute G>=3 toxicity | patients with late G>=3 toxicity | patients with G>=3 toxicity, timing unspecified | G>=3 AEs | patients with G>=3 AEs | details on G>=3 toxicity | details on G>=3 toxicity in RT field |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deming et al. | 2026 | Prospective | Tumor matrix proteoglycan accumulation and processing alters T cell effector function and the response to immunotherapy in patients with oligometastatic colorectal cancer | 10.1158/1078-0432.CCR-25-2780 | NCT02837263 | 15 | 64.0 | 49.2 | Colorectal cancer | oligometastatic, metastatic | Anti-PD-(L)1 mAb | Pembrolizumab | — | Missing | extra-cranial | liver | — | Missing | 40 | 60 | 5 | 5 | 5 | Missing | 8 | 12 | RT-related | — | — | 1 | any G3-4: 1 AE | any G3-4: 1pt |
any G3-4: biloma
|
any G3-4: biloma
|
| Lee et al. | 2026 | Prospective | The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II study | 10.1038/s41467-026-69294-3 | NCT02648282 | 54 | 64.2 | 19.6 | pancreas | primary | Anti-PD-(L)1 mAb | Pembrolizumab | plus GM-CSF-secreting allogeneic pancreatic cancer vaccine | 54 | extra-cranial | other | pancreas | 33 | 33 | 33 | 5 | 5 | 5 | 6.6 | 6.6 | 6.6 | Treatment-rel. | — | — | 6 | any G3: 7 AEs | any G3: 7 pts |
any G3: diabetic ketoacidosis, colitis, elevated liver enzymes, nephritis, pneumonitis, rash
|
unknown
|
| O'Kane et al. | 2026 | Prospective | Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib - A phase II trial (PEMRAD) | 10.1016/j.jhepr.2025.101658 | NCT03316872 | 18 | 66.5 | 25.3 | HCC | any | Anti-PD-(L)1 mAb | Pembrolizumab | — | 34 | extra-cranial | liver | — | 32.5 | 30 | 40 | 5 | 5 | 5 | 6.5 | 5.5 | 10 | Treatment-rel. | — | — | 4 | any G3: 3 AEs, any G5: 1 AE | any G3: 3 pts, any G5: 1 pt |
any G3: AST elevation, rash, aplastic anemia, any G5: myocarditis
|
unknown
|
| So et al. | 2026 | Prospective | Stereotactic Body Radiation Therapy With Pembrolizumab in Programmed Cell Death Protein 1 Inhibitor-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial | 10.1016/j.ijrobp.2025.12.043 | NCT03085719 | 18 | 59.0 | Missing | Head and neck cancer | oligometastatic | Anti-PD-(L)1 mAb | Pembrolizumab | — | 27 | extra-cranial | lung, liver, bone, other | head and neck | 40 | Missing | Missing | 5 | Missing | Missing | 8 | Missing | Missing | Treatment-rel. | — | — | 7 | any G3: 5 AEs, any G4: 2 AEs | any G3: 5 pts, any G4: 2 pts |
any G3: dysphagia, esophagitis, fatigue, neck pain, pain, any G4: laryngeal edema, tumor site bleeding
|
unknown
|
| Gandini et al. | 2024 | Prospective | Feasibility of stereotactic radiotherapy with pembrolizumab in patients with deficient mismatch repair/microsatellite unstable metastatic colorectal cancer | 10.1016/j.esmogo.2024.100069 | Missing | 11 | 66.0 | Missing | Colorectal cancer | Missing | Anti-PD-(L)1 mAb | Pembrolizumab | — | Missing | Missing | Missing | — | 20 | 20 | 20 | 2 | 2 | 2 | Missing | 5 | 15 | Treatment-rel. | — | — | 3 | any G3: 3 AEs | any G3: 3 pts |
any G3: bowel perforation in SABR field (could also be due to disease infiltration in intestinal wall and tumor shrinkage after RT), neuropathic pain after SABR on right biceps metastasis, pneumonia after lung SABR
|
any G3: bowel perforation in SABR field (could also be due to disease infiltration in intestinal wall and tumor shrinkage after RT), neuropathic pain after SABR on right biceps metastasis, pneumonia after lung SABR
|
| Siva et al. | 2022 | Prospective | Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial | 10.1016/j.eururo.2021.12.006 | NCT02855203 | 30 | 62.0 | 28 | Kidney cancer | oligometastatic | Anti-PD-(L)1 mAb | Pembrolizumab | — | 64 | extra-cranial | lung, adrenal gland, bone, muscle, LN unspecified, other | soft tissue | 20 | 20 | 20 | 1 | 1 | 1 | 20 | 20 | 20 | Treatment-rel. | — | — | 4 | any G3: 5 AEs | any G3: 4 pts |
any G3: pneumonitis, ALT increased, dyspnea, AP increased
|
—
|
| Sundahl et al. | 2019 | Prospective | Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma | 10.1016/j.eururo.2019.01.009 | NCT02826564 | 18 | 68.0 | 9 | Bladder cancer | metastatic | Anti-PD-(L)1 mAb | Pembrolizumab | — | 18 | extra-cranial | lung, axillary LN, abdominal LN, inguinal LN, other | local relapse at iliac veins, soft tissue lesion | 24 | 24 | 24 | 3 | 3 | 3 | 8 | 8 | 8 | Treatment-rel. | — | — | 1 | any G3: 1 AE | any G3: 1 pt |
any G3: lymphopenia
|
—
|
| Luke et al. | 2018 | Prospective | Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors | 10.1200/jco.2017.76.2229 | — | 73 | 62.0 | 5.5 | Breast cancer, Lung cancer, Colorectal cancer, Head and neck cancer, other | metastatic | Anti-PD-(L)1 mAb | Pembrolizumab | — | 151 | extra-cranial | lung, liver, spine, bone, cervical lymph nodes, other | mediastinum/thoracic, abdominal/pelvic | Missing | 30 | 50 | Missing | 3 | 5 | Missing | 10 | 15 | Treatment-rel. | 7 | — | — | acute G3: 6 AE | acute G3: 6 pt |
acute G3: pneumonitis, colitis, hepatic toxicity
|
—
|
| Nardin et al. | 2018 | Retrospective | Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases | 10.1097/cmr.0000000000000413 | — | 11 | 58.0 | 8.4 | Melanoma | metastatic | Anti-PD-(L)1 mAb | Pembrolizumab | — | 30 | intra-cranial | brain | — | Missing | 12 | 35 | Missing | 1 | 5 | Missing | 6 | 24 | RT-related | — | 1 | — | late G3: 1 AE | late G3: 1 pt |
late G3: Radiation necrosis
|
late G3: Radiation necrosis
|